The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis
Phase of Trial: Phase II
Latest Information Update: 07 May 2018
At a glance
- Drugs NB 001 (Primary)
- Indications Herpes labialis
- Focus Therapeutic Use
- Sponsors BlueWillow Biologics; NanoBio Corporation
- 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
- 28 Oct 2008 Data presented at the annual ICAAC/IDSA meeting in Washington, D.C, USA.
- 17 Mar 2008 Primary endpoint met; results reported in a NanoBio Corporation media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History